Search
betrixaban (Bevyxxa)
Indications:
- prevention of venous thromboembolism in hospitalized medical patients (FDA-approved June 2017)
Dosage:
- 160 mg PO once, then 80 mg/day for 35-42 days
Pharmacokinetics:
- maximum concentration 3-4 hours after oral dose
- 1/2life of 19-25 hours; 20 hrs [4]
Adverse effects: -increased risk of hemorrhage
Mechanism of action:
- factor Xa inhibitor
Interactions
drug adverse effects of antithrombotic agent(s)
General
coagulation factor Xa inhibitor
Database Correlations
PUBCHEM cid=10275777
References
- Green D
Prevention of Venous Thromboembolism in Hospitalized Medical
Patients.
NEJM Journal Watch. June 2, 2016
Massachusetts Medical Society
(subscription needed) http://www.jwatch.org
- Cohen AT, Harrington RA, Goldhaber SZ et al.
Extended thromboprophylaxis with betrixaban in acutely ill
medical patients.
N Engl J Med 2016 May 27
PMID: 27232649
- Gibson CM, Chi G, Halaby R et al
Extended-Duration Betrixaban Reduces the Risk of Stroke Versus
Standard-Dose Enoxaparin Among Hospitalized Medically Ill
Patients: An APEX Trial Substudy (Acute Medically Ill Venous
Thromboembolism Prevention With Extended Duration Betrixaban).
Circulation. 2017 Feb 14;135(7):648-655. Epub 2016 Nov 14.
PMID: 27881569
- Windle ML.
FDA New Drug and Biologic Approvals -- 2017 Year-in-Review
Medscape - Jan 11, 2018.
https://reference.medscape.com/viewarticle/890871
- U.S. Food and Drug Administration.
Novel Drug Approvals for 2017.
https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm537040.htm
- Medical Knowledge Self Assessment Program (MKSAP) 18,
American College of Physicians, Philadelphia 2018
- HIGHLIGHTS OF PRESCRIBING INFORMATION
BEVYXXA (betrixaban) capsules, for oral use.
https://www.bevyxxa.com/wp-content/uploads/2017/11/bevyxxa-betrixaban-capsules-prescribing-information-pdf.pdf